BCM
HRMY icon

Bayesian Capital Management’s Harmony Biosciences HRMY Stock Holding History

Bayesian Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,422
Closed -$314K – 837
2024
Q2 		$314K Buy
+10,422
New +$313K 0.04% 496
2023
Q2 		– Sell
-17,578
Closed -$574K – 916
2023
Q1 		$574K Buy
+17,578
New +$800K 0.07% 351
2022
Q2 		– Sell
-4,300
Closed -$209K – 909
2022
Q1 		$209K Buy
+4,300
New +$175K 0.03% 640

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bayesian Capital Management's HRMY Position: Q3 2024 in Review

Bayesian Capital Management sold out of Harmony Biosciences (HRMY) in Q3 2024, closing a stake of 10,422 shares — an estimated $314K sold.

Bayesian Capital Management first reported a position in HRMY in Q1 2022 and held it in 3 quarters. The position peaked at $574K in Q1 2023. 233 funds tracked by Wall St. Rank hold HRMY as of Q3 2024.

  • Bayesian Capital Management reported no remaining Harmony Biosciences position as of Q3 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 10,422 Harmony Biosciences shares in Q3 2024, an estimated $314K.
  • Bayesian Capital Management first reported a position in Harmony Biosciences in Q1 2022 and held it in 3 quarters.
  • Bayesian Capital Management's Harmony Biosciences position peaked at $574K in Q1 2023.
  • 233 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2024.

Based on Bayesian Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.